Technology area: Chemistry & Materials
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Tanvex Biopharma Usa Inc. maintains a company patent portfolio in the Chemistry & Materials technology area. There is currently 1 pending office action for this entity. This workload is handled by 1 distinct examiner within 1 distinct art unit, indicating that the company's current prosecution efforts are focused on a 1 technical area. This type of concentrated activity often reflects a strategic focus on a specific chemical or material science innovation.
The busiest examiner for this portfolio is GERMAIN, ADAM ADRIEN, who is responsible for 1 busiest examiner pending office action. This figure is identical to the total 1 pending office action for the company. Because there is only 1 distinct examiner and 1 distinct art unit, the company's current patent office activity is entirely concentrated under the review of this 1 individual. Practitioners should note that the company's immediate success in securing patent rights is tied to the specific examination process of this examiner within the chemistry sector.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GERMAIN, ADAM ADRIEN | 1 | 36.1% | +10.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17625655 | TEMPERATURE-CONTROLLED PURIFICATION OF GRANULOCYTE-COLONY STIMULATING FACTOR | GERMAIN, ADAM ADRIEN | 35d overdue |
| Art Unit | Apps |
|---|---|
| 1777 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17625655 | TEMPERATURE-CONTROLLED PURIFICATION OF GRANULOCYTE-COLONY STIMULATING FACTOR | GERMAIN, ADAM ADRIEN | 1777 | §103 | Non-Final OA | 35d overdue | Pending | Jan 07, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTanvex Biopharma Usa Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Adam Adrien Germain has the most, with 1 of Tanvex Biopharma Usa Inc.'s pending office actions.
Mostly Chemistry & Materials (USPTO Tech Center 1700), based on where its pending office actions are examined.